Hepatocellular carcinoma in Hepatitis C genotype 4 after viral clearance and in absence of cirrhosis: Two case reports

Cases Journal

Volumn 2, Issue 9, 2009, Pages

  Derbala, Moutaz ^a,b   Amer, Aliaa ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CASE REPORT; CHEMOEMBOLIZATION; ERADICATION THERAPY; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIXED INFECTION; SCHISTOSOMIASIS; VIRUS TYPING;

EID: 77953473448     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.4076/1757-1626-2-7927     Document Type: Article

References (20)

1. Ezzat S, Abdel-Hamid M, Eissa SA, Mokhtar N, Labib NA, El-Ghorory L, Mikhail NN, Abdel-Hamid A, Hifnawy T, Strickland GT, Loffredo CA: Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health 2005, 208:329-39.
2. Omata M, Yoshida H, Shiratori Y: Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 2005, 3:S141-143.
3. Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN: Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol 2007, 22:669-675.
4. Hirakawa M, Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Kumada H: Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med 2008, 47:1637-1643.
5. Szabo E, Paska C, Kaposi Novak P, Schaff Z, Kiss A: Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol Oncol Res 2004, 10:5-11.
6. Manesis EK, Papatheodoridis GV, Touloumi G, Karafoulidou A, Ketikoglou J, Kitis GE, Antoniou A, Kanatakis S, Koutsounas SJ, Vafiadis IHEPNET. Greece Cohort Study: For the HEPNET. Greece Cohort Study. Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet. Greece cohort study. Aliment Pharmacol Ther 2009, 29:1121-1130.
7. Vukotic R, Gramenzi A, Vitale G, Cursaro C, Serra C, Biselli M, Scuteri A, Andreone P, Bernardi M: Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin. Liver Int 2008, 28:407-411.
8. Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H: Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 2005, 20:752-758.
9. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P, Fisher R: Genes involved in viral carcinogenesis and tumor initiation in Hepatitis C Virusinduced Hepatocellular Carcinoma. Mol Med 2009, 15:85-94.
10. Gimenez-Barcons M, Franco S, Suárez Y, Forns X, Ampurdanès S, Puig-Basagoiti F, Sanchez-Fueyo A, Barrera JM, Llovet JM, Bruix J, Sanchez-Tapias JM, Rodes J, Saiz JC: High Amino Acid Variability Within the NS5A of Hepatitis C Virus (HCV) Is Associated With Hepatocellular Carcinoma in Patients With HCV-1b-Related Cirrhosis. Hepatology 201, 34:158-167.
11. Genovese D, Dettori S, Argentini C, Villano U, Chionne P, Angelico M, Rapicetta M: Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol 205, 43:1902-1909.
12. Zekri AR, Bahnassy AA, Shaarawy SM, Mansour OA, Maduar MA, Khaled HM, El-Ahmadi O: Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma. J Med Microbiol 200, 49: 89-95.
13. Sieja KS, Everson GT: De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy. Dig Dis Sci 206, 51:60-602.
14. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999, 131:174-181.
15. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH, Chen WJ, Changchien CS: Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 206, 13:409-414.
16. Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, Martínez I, Rodrigo L: Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 203, 37:520-527.
17. Esaki T, Suzuki N, Yokoyama K, Iwata K, Irie M, Anan A, Nakane H, Yoshikane M, Nishizawa S, Ueda S, Sohda T, Watanabe H, Sakisaka S: Hepatocellular carcinoma in a patient with liver cirrhosis associated with negative serum HCV tests but positive liver tissue HCV RNA. Intern Med 204, 43:279-282.
18. Stuart C, Gordon MD: Occult Viral Hepatitis and Noncirrhotic Hepatocellular Carcinoma. Am J Gastroenterol 205, 10:1754-1757.
19. Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez-Iñigo E, de Lucas S, Salas C, Jiménez-Heffernan JA, Pérez-Mota A, Graus J, López-Alcorocho JM, Carreño V: Occult hepatitis C virus infection in patients in whom the etiology of persistent abnormal results of liver-function tests is unknown. J Infect Dis 204, 189:7-14.
20. Barria MI, Vera-Otarola J, León U, Vollrath V, Marsac D, Riquelme A, Lopez-Lastra M, Soza A: Influence of extrahepatic viral infection on the natural history of hepatitis C. Ann Hepatol 208, 7:136-143.